JT Pharmaceuticals, Inc.

Mount Pleasant, SC 29464

SBIR Award Summary

Total Number of Awards 7
Total Value of Awards $4.26MM
First Award Date 09/16/14
Most Recent Award Date 08/15/17

Key Personnel

Last Name Name Awards Contact
DIX THOMAS A. DIX 7
YU SHAN P. YU 3

7 Awards Won

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PAR-14-209
Budget: 08/15/17 - 04/30/18

ABSTRACT While acute stroke is a leading cause of human death and disability in the United States, unfortunately, clinical therapies for stroke are limited and unsatisfactory. The overwhelming failures of stroke treatments in clinical trials strongly indicate that, to battle this multifaceted brain disorder, novel strategies that target multipl...

Phase 2 STTR

Agency: Department of Health & Human Services
Topic: PA-14-072
Budget: 05/01/16 - 04/30/17

? DESCRIPTION (provided by applicant): Stroke is a leading cause of human death and disability in the United States while clinical therapy for acute stroke is limited and unsatisfactoy. The many failures in clinical trials strongly endorse the idea that to battle this multifaceted bran disorder, novel strategies that target multiple cell types...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PAR-14-088
Budget: 03/01/16 - 02/28/17

DESCRIPTION (provided by applicant): Neuropathic pain management is a major unmet clinical need. Classically used medications (opioids and non-opioids/NSAIDs) have major side effects associated with their use, and many individuals do not respond to any medications. Neuropathic pain drugs with novel mechanisms of action are being sought as altern...

Phase 2 STTR

Agency: Department of Health & Human Services
Topic: PA-14-072
Budget: 05/01/15 - 04/30/16

DESCRIPTION (provided by applicant): Stroke is a leading cause of human death and disability in the United States while clinical therapy for acute stroke is limited and unsatisfactoy. The many failures in clinical trials strongly endorse the idea that to battle this multifaceted bran disorder, novel strategies that target multiple cell types and...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PAR-14-088
Budget: 03/01/15 - 02/29/16

DESCRIPTION (provided by applicant): Neuropathic pain management is a major unmet clinical need. Classically used medications (opioids and non-opioids/NSAIDs) have major side effects associated with their use, and many individuals do not respond to any medications. Neuropathic pain drugs with novel mechanisms of action are being sought as altern...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-13-088
Budget: 09/23/14 - 09/22/15

DESCRIPTION (provided by applicant): Neuropathic pain management is a major unmet clinical need. Classically used medications, including opioids and non-opioids (primarily NSAIDs), have major side effects associated with their use, and many individuals do not respond to any medications. Neuropathic pain drugs with novel mechanisms of action are ...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-13-234
Budget: 09/16/14 - 07/31/15

DESCRIPTION (provided by applicant): Treatment of peripheral pain of various origins remains a major unmet medical need, affecting tens to hundreds of millions of people nationwide at some time during their lives. Kappa-opioid agonists have been shown in peripheral pain models to be particularly efficacious but suffer from centrally mediated eff...